The PROSPECT II study was published in the March 13th issue of The Lancet, finding that IVUS+NIRS imaging can detect plaques at increased risk for future adverse cardiac outcomes.VIEW ARTICLEVIEW ARTICLE
Finding a path to success requires the best tools available.
Infraredx, a Nipro Company, and B. Braun Interventional Systems Inc., an Affiliate of B. Braun Medical Inc., Announce Strategic U.S. Collaboration to Execute the IDE Clinical Trial for the SeQuent® Please ReX™ Drug Coated PTCA Balloon Catheter.
Panel Discussion: Integrating NIRS in Clinical Practice
Panel Moderator: Takashi Akasaka, MD, PhD
Panel Moderator: Ryan D. Madder, MD
Panel Moderator: Ron Waksman, MD, FSCAI
Panelist: Carlo Di Mario, MD
Panelist: James A. Goldstein, MD, FSCAI
Panelist: John McB Hodgson, MD, MSCAI
Panel Discussion: Now That We Can Identify Vulnerable Plaque, What’s Next?
Moderator: Ryan D. Madder, MD
Moderator: Lorenz Räber, MD, PhD
Panelist: Takashi Akasaka, MD, PhD
Panelist: Peter Libby, MD
Panelist: Gregg W. Stone, MD, FSCAI
Panelist: Ron Waksman, MD, FSCAI
Panelist: Robert L. Wilensky, MD